How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries? January 24, 2023 Issue Brief The brief provides a quick explainer of the prescription drug provisions in the Inflation Reduction Act signed into law on August 16, 2022 and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
Coverage Implications of Policies to Lower the Age of Medicare Eligibility May 21, 2021 Issue Brief This data note looks at the coverage implications of policies to lower the age of Medicare eligibility as proposed by President Biden during the presidential campaign.
Could Consumer Assistance be Helpful to People Facing Medical Debt? July 14, 2022 Blog Most (53%) adults with health care debt say they have received a medical or dental bill they thought contained an error at some point in the past 5 years, and most say a state consumer assistance program would be helpful to them.
Marketplace Insurers are Proposing a 6% Average Premium Hike for 2024 and Pointing to Inflation as a Key Driver of Costs August 4, 2023 News Release ACA Marketplace insurers are requesting a median premium increase of 6% for 2024, according to a new KFF analysis of the preliminary rate filings. Insurers’ proposed rate changes – most of which fall between 2% and 10% – may change during the review process. Although most Marketplace enrollees receive subsidies…
Large Majorities Across Parties Favor Allowing the Federal Government to Negotiate Drug Prices, Even After Hearing Common Arguments About It October 12, 2021 News Release Most of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the…
Out-of-pocket spending on insulin among people with private insurance March 24, 2022 Issue Brief This analysis of insurance claims data finds that Congressional proposals to set a $35 per month cap on what people pay out of pocket for insulin would provide financial relief to at least 1 out of 5 insulin users with different types of private health insurance.
The Uncertain Future of Policies to Promote Access and Affordability Put in Place During the COVID-19 Pandemic May 19, 2022 Perspective In this column for the JAMA Health Forum, Larry Levitt highlights four changes implemented during the COVID-19 pandemic that helped to make health care more accessible and affordable and the prospects for those changes to telehealth, COVID-19 coverage, Medicaid and marketplace premiums continuing beyond the pandemic’s end.
Surprise Medical Bills are Ending, But Controversy Continues January 20, 2022 Perspective In this column for the JAMA Health Forum, Larry Levitt examines how the No Surprises Act that prohibits unexpected out-of-network charges for patients could lead to lower payment rates and revenues for some doctors and other care providers.
Use of ACA preventive services potentially affected by Braidwood v. Becerra May 25, 2023 Issue Brief This analysis finds that about 10 million privately insured people received at least one ACA preventive service or drug that could be affected by a now-stayed U.S. District Court ruling, which found the Affordable Care Act’s (ACA) requirement to cover certain preventive services without any cost sharing to be partially unconstitutional.
About 1 in 20 People with Private Insurance Received Services that Could be Affected by a District Court Ruling Limiting the ACA’s Preventive Services Mandate May 25, 2023 News Release A new KFF analysis finds about 1 in 20 privately insured people (5.7%) received at least one ACA preventive service or drug that could be affected by a now-stayed U.S. District Court ruling in Braidwood Management v. Becerra, which found the Affordable Care Act’s (ACA) preventive services mandate partially unconstitutional.…